Skip to main content
Erschienen in:

05.11.2018 | short review

The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer

verfasst von: Dr. Clemens Dormann, PD Dr. Karl J. Aichberger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.
Literatur
Metadaten
Titel
The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
verfasst von
Dr. Clemens Dormann
PD Dr. Karl J. Aichberger
Publikationsdatum
05.11.2018
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0448-3

Weitere Artikel der Ausgabe 4/2018

memo - Magazine of European Medical Oncology 4/2018 Zur Ausgabe